Medicines for Europe calls for Biotech Act reforms to address 'biosimilar void'

Medicines for Europe calls for urgent reforms in the EU Biotech Act to address a critical biosimilar development gap threatening patient access, healthcare sustainability, and European biotech leadership. Key recommendations include regulatory streamlining, increased EU biotech manufacturing funding, opposition to SPC extension proposals, and skills development to counter rising global competition.

This Wire brief sits within Fusion42's coverage of Biotech.